This is an observational, multicenter, international and retrospective study, that aims to collect data on clinical and pathological characteristics, treatment regimens, outcome, and prognostic factors (clinical, biomarkers and/or radio-metabolic) in patients affected by PBL.
This study is an International, multicenter, observational, retrospective trial on patients affected by PBL. The information collected aim to obtain data from the real-life diagnosis, staging, management and treatment and outcome of PBL patients. A centralized pathological review of pathological samples is planned to define the rate of accurate diagnosis and to define a recommended immunohistochemical diagnostic panel for PBL. In addition, exploratory analysis will be performed to better characterize PBL.
Study Type
OBSERVATIONAL
Enrollment
200
Overall Survival (OS)
OS is defined as the time from the diagnosis to death for any cause or last clinical contact for censored patients.
Time frame: 36 months
ECOG-PS
Proportion of Performance Status: from 0 (fully active) to 4 (Completely disabled)
Time frame: 36 months
Ann Arbor Stage
Proportion of stage: from I (better) to IV (worse)
Time frame: 36 months
Kidney and/or adrenal gland involvement
Proportion of the presence of involvement
Time frame: 36 months
Diagnostic liquor
Proportion of the presence of liquor
Time frame: 36 months
Splenic involvement
Proportion of spenic involvement
Time frame: 36 months
Type of chemotherapy (CHT) regimen
Proportion of CHT administered
Time frame: 36 months
Complete remission rate (CR)
CR at the end of treatment
Time frame: 36 months
Overall response rate (ORR)
ORR is defined as the proportion of patients who have a partial or complete response to therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
IRCCS Centro di Riferimento Oncologico di Aviano, Divisione di Oncologia e dei Tumori immuno-correlati
Aviano, PN, Italy
RECRUITINGOspedale C.e G. Mazzoni, U.O.C. di Ematologia
Ascoli Piceno, Italy
RECRUITINGASST Spedali Civili di Brescia, Ematologia
Brescia, Italy
ACTIVE_NOT_RECRUITINGA.O. S. Croce e Carle, S.C. di Ematologia e Trapianto di Midollo Osseo
Cuneo, Italy
RECRUITINGAzienda Ospedaliera Universitaria Careggi, Unità funzionale di Ematologia
Florence, Italy
RECRUITINGASST -Fatebenefratelli - Polo Luigi Sacco Oncologia
Milan, Italy
RECRUITINGASST Grande Ospedale Metropolitano Niguarda, SC Ematologia
Milan, Italy
RECRUITINGIstituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia
Milan, Italy
ACTIVE_NOT_RECRUITINGOspedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Ematologia
Milan, Italy
ACTIVE_NOT_RECRUITINGFondazione IRCCS San Gerardo dei Tintori, Ematologia
Monza, Italy
RECRUITING...and 13 more locations
Time frame: 36 monts
Progression-free survival (PFS)
PFS is defined as time from diagnosis to progression, relapse or death for any cause and last clinical contact for censored cases,
Time frame: 36 months
Validation of IPI and CNS-IPI score by means of Cox PH regression on OS and PFS
IPI (international prognostic Index) ranging from 0 (lower risk) to 5 points (greater risk); CNS-IPI score (Central Nervous System IPI) ranging from 0 (lower risk) to 6 points (greater risk).
Time frame: 36 months
Frequencies of HIV and EBV at relapse
Frequencies of HIV and EBV at relapse
Time frame: 36 months